Physician profile

Baylee Baldwin

Physician Assistant · Billings, MT

NPI 1447913439

$2,833.35

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

See the full distribution for Physician Assistant

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$319.56

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $2,291.00 2022
Abbvie INC. $181.30 2022-2024
Teva Pharmaceuticals USA, INC. $171.84 2022-2023 Austedo Xr, Austedo
Merz Pharmaceuticals, LLC $81.88 2022-2024 Xeomin
Novartis Pharmaceuticals Corporation $48.80 2022
Amgen INC. $33.77 2022-2024 Evenity, Prolia
Lundbeck LLC $24.76 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Baylee Baldwin

$2,833.35

in general payments reported 2019-2025

Years
2022-2024
Top company
Abbott Laboratories

https://glasscript.com/doctor/11272025/baylee-baldwin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.